Future change in ownership in Episurf

Episurf Medical AB (“Episurf”) has today been informed about the intention of its largest shareholder Serendipity Ixora AB (“Ixora”) to wind-up its operations and in conjunction thereto distribute its holdings of Episurf shares to its shareholders. Today, Ixora owns 4,601,519 A-shares in Episurf, corresponding to 14.8 per cent of the shares and 33.2 per cent of the votes in Episurf.

The Board of Directors of Ixora is currently assessing an optimal structure for the wind-up process and distribution, and intends to summon an extraordinary general meeting in Ixora to decide on the matter shortly. The distribution is expected to take place within three-month period from the day of the decision at an extra general meeting. However, no date has yet been set for the distribution. Ixora has approximately 350 shareholders and is controlled by Serendipity Group AB, who owns 45.8 per cent of the shares.

For more  information, please contact:
 

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

Tags:

About Us

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.